Dostarlimab in advanced/recurrent (A/R) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study

被引：0

作者：

Oaknin, Ana ^{[1
]}

Pothuri, Bhavana ^{[2
,3
]}

Gilbert, Lucy ^{[4
]}

Sabatier, Renaud ^{[5
]}

Ghamande, Sharad ^{[6
]}

Gravina, Adriano ^{[7
]}

Calvo, Emiliano ^{[8
]}

Banerjee, Susana ^{[9
,10
]}

Mangan, Niamh ^{[11
]}

Miller, Rowan E. ^{[12
]}

Pikiel, Joanna ^{[13
]}

Mirza, Mansoor R. ^{[14
]}

Duan, Tao ^{[15
]}

Zildjian, Sybil ^{[16
]}

Zografos, Eleftherios ^{[17
]}

Veneris, Jennifer ^{[16
]}

Tinker, Anna V. ^{[18
]}

机构：

[1] Hosp Univ Vall dHebron, Gynaecol Canc Programme, Vall dHebron Inst Oncol VHIO, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain

[2] NYU Langone Hlth, Gynecol Oncol Grp GOG, New York, NY USA

[3] NYU Langone Hlth, Dept Obstet Gynecol, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA

[4] McGill Univ, Div Gynecol Oncol, Hlth Ctr, Montreal, PQ, Canada

[5] Aix Marseille Univ, Dept Med Oncol, Marseille, France

[6] Augusta Univ, Dept Obstet & Gynecol, Georgia Canc Ctr, Augusta, GA USA

[7] Ist Nazl Tumouri Fdn G Pascale, Clin Trial Unit, Naples, Italy

[8] Ctr Integral Oncol Clara Campal, START Madrid CIOCC, Madrid, Spain

[9] Royal Marsden NHS Fdn Trust, London, England

[10] Inst Canc Res, London, England

[11] GSK, Melbourne, Australia

[12] UCL, St Bartholomews Hosp London, London, England

[13] Reg Ctr Oncol, Dept Chemotherapy, Gdansk, Poland

[14] Rigshosp, Copenhagen Univ Hosp, Nord Soc Gynaecol Oncol Clin Trial Unit, Dept Oncol, Copenhagen, Denmark

[15] GSK, Pennington, NJ USA

[16] GSK, Waltham, MA USA

[17] GSK, London, England

[18] Univ British Columbia, Dept Med, British Columbia Canc, Vancouver Ctr, Vancouver, BC, Canada

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 18卷

基金：

芬兰科学院;

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

218

引用

页码：133 / 134

页数：2

共 50 条

[41] Efficacy of PD-1 Inhibitor Combined with Bevacizumab in Treatment of Advanced Endometrial Cancer Patients with Mismatch Repair Deficiency (dMMR)/High-Level Microsatellite Instability (MSI-H)
Liao, Ying
Zhu, Changhua
Song, Xiaoxia
Ruan, Jiugen
Ding, Yao
Chen, Yuan
Yang, Qiujuan
MEDICAL SCIENCE MONITOR, 2022, 28
[42] Literature review and meta-analyses of the prevalence of microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) for colorectal (CRC), gastric (GC), endometrial (EC) and ovarian cancers (OC) in Chinese population
Liu, Xiaoqiao
Fan, Jiaqi
Liaw, Kai-Li
Xu, Mo
Zhou, Yu
Amonkar, Mayur
Zeng, Gefei
CANCER RESEARCH, 2019, 79 (13)
[43] FREQUENCY OF AND TESTING PATTERNS FOR MICROSATELLITE INSTABILITY HIGH (MSI-H) AND DEFICIENT MISMATCH REPAIR (DMMR) AMONG SOLID TUMORS IN A US COMMUNITY ONCOLOGY SETTING
Chase, M.
Vasudevan, A.
Amonkar, M.
Myer, N.
Wang, T.
Prabhu, V
Turzhitsky, V
Spira, A.
VALUE IN HEALTH, 2022, 25 (07) : S452 - S452
[44] Pembrolizumab in microsatellite instability high (MSI-H)/ mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study.
Maio, Michele
Ascierto, Paolo Antonio
Manzyuk, Ludmila
Motola-Kuba, Daniel
Penel, Nicolas
Cassier, Philippe A.
Bariani, Giovanni
De Jesus-Acosta, Ana
Doi, Toshihiko
Longo, Federico
Miller, Wilson H.
Oh, Do-Youn
Gottfried, Maya
Wang, Ruixue
Jin, Fan
Norwood, Kevin Glen
Marabelle, Aurelien
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[45] SAFETY PROFILE OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH DNA MISMATCH REPAIR-DEFICIENT/MICROSATELLITE INSTABILITY-HIGH (DMMR/MSI-H) METASTATIC COLORECTAL CANCER (MCRC) IN CHECKMATE-142
Brutcher, Edith
Khoukaz, Taline
Hartman, Leighanne
ONCOLOGY NURSING FORUM, 2018, 45 (02)
[46] Antitumor activity of dostarlimab in patients with advanced or recurrent mismatch repair-deficient or -proficient cancer by prior therapy: Results from the GARNET study
Hanker, Lars
Oaknin, Ana
Gilbert, Lucy
Tinker, Anna
Brown, Jubilee
Matthews, Cara
Press, Joshua
Sabatier, Renaud
O'malley, David
Samouelian, Vanessa
Boni, Valentina
Duska, Linda
Ghamande, Sharad
Ghatage, Prafull
Kristeleit, Rebecca
Leath, Charles, III
Veneris, Jennifer
Duan, Tao
Im, Ellie
Pothuri, Bhavana
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 56 - 56
[47] Analysis of candidate target genes for mononucleotide repeat mutation in microsatellite instability-high (MSI-H) endometrial cancer
Kawaguchi, Makiko
Banno, Kouji
Yanokura, Megumi
Kobayashi, Yusuke
Kishimi, Arisa
Ogawa, Seiji
Kisu, Iori
Nomura, Hiroyuki
Hirasawa, Akira
Susumu, Nobuyuki
Aoki, Daisuke
INTERNATIONAL JOURNAL OF ONCOLOGY, 2009, 35 (05) : 977 - 982
[48] Pancytopenia And Limbic Encephalopathy Complicating Immunotherapy For Clear Cell Endometrial Cancer With Microsatellite Instability-High (MSI-H)
Kanbour, Aladdin
Rasul, Kakil Ibrahim
Albader, Salha Bujassoum
Al Sulaiman, Reem Jawad
Melikyan, Gayan
Farghaly, Hanan
Lengyel, Zsolt
Al Rimawi, Yousef
Soliman, Dina
Omar, Nabil Elhadi
ONCOTARGETS AND THERAPY, 2019, 12 : 9965 - 9973
[49] Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability-high tumors: A combined analysis of two cohorts in the GARNET study.
Berton, Dominique
Banerjee, Susana N.
Curigliano, Giuseppe
Cresta, Sara
Arkenau, Hendrik-Tobias
Abdeddaim, Cyril
Kristeleit, Rebecca Sophie
Redondo, Andres
Leath, Charles A.
Torres, Antonio Anton
Guo, Wei
Im, Ellie
Andre, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[50] Genomic landscapes to characterize mismatch-repair deficiency (dMMR)/microsatellite instability-high (MSI-H) gastrointestinal (GI) cancers stratified by tumor mutation burden (TMB)
Wang, Jingyuan
Xiu, Joanne
Farrell, Alex Patrick
Battaglin, Francesca
Arai, Hiroyuki
Millstein, Joshua
Soni, Shivani
Zhang, Wu
Shields, Anthony F.
Grothey, Axel
Weinberg, Benjamin Adam
Marshall, John
Lou, Emil
Khushman, Moh'd M.
Sohal, Davendra
Hall, Michael J.
Oberley, Matthew James
Spetzler, David
Lenz, Heinz-Josef
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →